Drug Profile
Research programme: anabolic peptides - Osteopharm
Alternative Names: Anabolic peptides research programme - OsteopharmLatest Information Update: 18 Jul 2006
Price :
$50
*
At a glance
- Originator Osteopharm
- Class
- Mechanism of Action Osteogenesis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 18 Jul 2006 No development reported - Preclinical for Postmenopausal osteoporosis in Canada (unspecified route)
- 22 Mar 2002 Osteopharm has been sold by GenSci Regeneration Sciences
- 02 Mar 1999 New profile